Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating Expenses:    
Research and development $ 240,905 $ 365,186
Research and development - related parties 135,455 170,542
General and administrative 1,996,608 1,556,740
Total Operating Expenses 2,372,968 2,092,468
Loss From Operations (2,372,968) (2,092,468)
Other Income (Expense):    
Other income 6,391 1,039,364
Interest expense (2,655) (16,449)
Change in fair value of derivative liabilities (191)
Total Other Income (Expense), Net 3,736 1,022,724
Loss Before Income Taxes (2,369,232) (1,069,744)
Income tax benefit
Net Loss (2,369,232) (1,069,744)
Other Comprehensive Income (Loss):    
Foreign currency translation adjustments (64,691) 6,460
Total Comprehensive Loss $ (2,433,923) $ (1,063,284)
Basic and Diluted Net Loss per Common Share    
Basic (in Dollars per share) $ (0.67) $ (1.68)
Diluted (in Dollars per share) $ (0.67) $ (1.68)
Weighted Average Number of Common Shares Outstanding:    
Basic (in Shares) 3,539,331 638,339
Diluted (in Shares) 3,539,331 638,339